Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modern Diagnostic & Research CentreBOM:544673 15 Return-on-Tangible-Equity is 10.86% as of Mar. 2026, which is 70% below its 10-year median of 36.20. GuruFocus rates BOM:544673 with a GF Score™ of 15/100. The stock has 7 warning signs investors should review. Among 187 Medical Diagnostics & Research companies, Modern Diagnostic & Research Centre ranks better than 60.96% on this metric.
The historical rank and industry rank for Modern Diagnostic & Research Centre's Return-on-Tangible-Equity or its related term are showing as below:
BOM:544673'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -96.67 Med: 36.2 Max: 68.63
Current: 5.43
During the past 4 years, Modern Diagnostic & Research Centre's highest Return-on-Tangible-Equity was 68.63%. The lowest was -96.67%. And the median was 36.20%.
BOM:544673's Return-on-Tangible-Equity is ranked better than 60.96% of 187
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.34
vs BOM:544673: 5.43
Modern Diagnostic & Research Centre (BOM:544673) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Modern Diagnostic & Research Centre Return-on-Tangible-Equity Related Terms
Modern Diagnostic & Research Centre Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Diagnostic & Research Centre Return-on-Tangible-Equity Chart
Modern Diagnostic & Research Centre Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Return-on-Tangible-Equity
-96.67
68.63
58.69
13.70
Modern Diagnostic & Research Centre Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Return-on-Tangible-Equity
0.00
0.00
0.00
10.86
BOM:544673 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Modern Diagnostic & Research Centre's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modern Diagnostic & Research Centre Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Modern Diagnostic & Research Centre's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Modern Diagnostic & Research Centre's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.86% mean?
Modern Diagnostic & Research Centre (BOM:544673) has a Return-on-Tangible-Equity of 10.86% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Modern Diagnostic & Research Centre and its competitors. This is 70% below median its historical median of 36.20. According to the industry distribution chart, Modern Diagnostic & Research Centre ranks #73 out of 187 companies in the Medical Diagnostics & Research industry, placing it in the top 39%.
Is Modern Diagnostic & Research Centre's Return-on-Tangible-Equity too high?
Modern Diagnostic & Research Centre's current Return-on-Tangible-Equity of 10.86% is 70% below median its 10-year median of 36.20. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.34. Modern Diagnostic & Research Centre's value of 10.86% is 3094.1% above this industry median. Based on the distribution chart, Modern Diagnostic & Research Centre ranks #73 out of 187 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Modern Diagnostic & Research Centre has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Modern Diagnostic & Research Centre's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Modern Diagnostic & Research Centre ranks #73 out of 187 companies for Return-on-Tangible-Equity. This puts Modern Diagnostic & Research Centre in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.34. Modern Diagnostic & Research Centre's value of 10.86% is 3094.1% above this benchmark. While the company's 10-year median is 36.20 vs. the industry median of 0.34, Modern Diagnostic & Research Centre has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.34, based on 187 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modern Diagnostic & Research Centre's current Return-on-Tangible-Equity of 10.86% is 3094.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Modern Diagnostic & Research Centre and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modern Diagnostic & Research Centre's current Return-on-Tangible-Equity is 10.86%, which is 70% below median its own 10-year median of 36.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Diagnostic & Research Centre stock overvalued right now?
Modern Diagnostic & Research Centre (BOM:544673) has a current Return-on-Tangible-Equity of 10.86%. The current Return-on-Tangible-Equity is 10.86%, which is 70% below median its 10-year median of 36.20 and 3094.1% above the Medical Diagnostics & Research industry median of 0.34. Modern Diagnostic & Research Centre's overall GF Score™ is 15/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Modern Diagnostic & Research Centre (BOM:544673), the current Return-on-Tangible-Equity is 10.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modern Diagnostic & Research Centre Ltd is a services provider in diagnostic and related healthcare tests services in India. It offers a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through Its integrated, nationwide network, it offers a complete range of diagnostic facilities in radiology and pathology. The company provides healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
15GF Score
Get the complete analysis for BOM:544673
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544673 has been successfully added to your 
